Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Kicks Off Phase III Trial For Stelara Rival

Chinese Biosimilars Developer Begins Study For BAT2206 Ustekinumab Candidate

Executive Summary

Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.

You may also be interested in...



Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab

Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.

Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar

Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.

Samsung Bioepis Is Latest To Move Ustekinumab Into Phase III

Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.

Related Content

Topics

UsernamePublicRestriction

Register

GB151095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel